Categories
Funds Funds

The Hartford Capital Appreciation Fund Class C Soaring High, But a Little Safety Won’t Hurt

Process:

Lingering uncertainty about this factor-oriented fund’s potential for sleeve manager and style changes keeps its Process rating at Below Average. 

Between March 2013 and the end of 2017, Wellington Management’s investment strategy and risk group altered this fund from a wide-ranging, single-manager offering to its current form. Six managers now run separate sleeves of the portfolio. The sleeves vary in size, but each is concentrated in 50 or fewer stocks and has distinct emphases, whether value or growth, market cap, or domicile. Gregg Thomas, who took over the investment strategy and risk group in late 2018, controls the aggregate portfolio’s characteristics by adjusting the size of Thomas Simon’s sleeve, which uses a multifactor approach to complement the five other sleeves, and by shifting assets among or even swapping managers to match the Russell 3000 Index’s risk profile. The idea is to let the stock-pickers rather than size, sector, or factor bets drive performance. 

Although regular line-up changes have made it difficult to assess the strategy, there could be more stability in the future. Thomas now envisions making a manager change every three to five years, on average, down from every two years when he took over in 2018. The current roster has been stable only since late 2019, however, when Thomas changed two managers, including replacing a veteran global manager with a relatively inexperienced mid-cap value manager.

Portfolio:

A rotating cast of six sleeve managers has had collective charge of the portfolio since the late 2017 retirement of long-time sole manager Saul Pannell. His departure concluded a transition that started in March 2013 when Wellington Management’s investment strategy and risk group began apportioning 10% of the fund’s assets to different managers–a total that hit 50% by mid-2014 and stayed there until early 2017, after which the group gradually redirected Pannell’s remaining assets. 

The transition to a multimanager offering beginning in 2013 ballooned the portfolio’s number stocks to 350- plus before falling to around 200 since April 2017. The fund’s sector positioning versus the Russell 3000 Index began to moderate in 2013 and has since typically stayed within about 5 percentage points of the benchmarks. Its tech underweighting dipped to nearly 10 percentage points in November 2020 but was back to around 5 percentage points by late 2021. 

Industry over- and underweighting’s tend to stay within 4 percentage points. In late 2021, however, the portfolio was 5.6 percentage points light in tech hardware companies, entirely because it did not own Apple AAPL. The fund’s non-U.S. stock exposure neared 30% of assets in 2014 but has been in the single digits since late 2019, when a domestic-oriented mid-cap value sleeve manager replaced a sleeve manager with a global focus. 

People:

The fund earns an Above Average People rating because its subadvisor’s multimanager roster includes veterans who have built competitive records elsewhere at sibling strategies where they also invest alongside shareholders. Those managers, however, serve this fund at the behest of Wellington Management’s Gregg Thomas. He took over capital allocation and manager selection duties at year-end 2018, when he became director of the investment strategy and risk group. Between March 2013 and year-end 2017, this group changed the fund from a wide-ranging single-manager offering to a multimanager strategy. Six managers now oversee separate sleeves of the portfolio. Growth investor Stephen Mortimer, dividend-growth stickler Donald Kilbride, and contrarian Gregory Pool each run 15%-25% of assets; mid-cap specialists Philip Ruedi and Gregory Garabedian 10%-20% each; and Thomas Simon uses a multifactor approach on 5%-20% assets to round out the whole portfolio’s characteristics. Thomas monitors those characteristics and redirects assets or even swaps managers to match the Russell 3000 Index’s risk profile, leaving it up to the stock-pickers to drive outperformance. That’s led to considerable manager change here. Of the original seven sleeve managers the investment strategy and risk group installed in March 2013, only Donald Kilbride remains; and the current six-person roster has been in place only since Sept. 30, 2019.

Performance:

This multimanager offering has struggled since Wellington Management’s Gregg Thomas took over capital allocation and manager selection duties at year-end 2018. Through year-end 2021, the A shares’ 22% annualized gain lagged the Russell 3000 Index and large-blend category norm by 3.8 and 0.8 percentage points, respectively, with greater volatility than each. The fund also has not distinguished itself since its current six-person sleeve manager stabilized on Sept. 30, 2019.

The fund was competitive in 2019’s rally and in 2020’s market surge following the brief but severe coronavirus-driven bear market. Of those two calendar years, the fund fared best against peers in 2020, with a top-quartile showing. But in neither year did it beat the index. 

Results in 2021 were then relatively poor. The A shares’ 15.2% gain trailed the index by 10.5 percentage points and placed near the peer group’s bottom. It was an off year for the sleeve managers’ stock picking. Especially painful were modest positions in biotechnology stocks Chemocentryx CCXI and Allakos ALLK, whose shares both tumbled after disappointing clinical trial data. 

The fund was lacklustre during its four-plus years of transition from a single-manager offering under Saul Pannell to its current format. From March 2013 to Pannell’s 2017 retirement, its 13.1% annualized gain lagged the index by 1.5 percentage points and placed in the peer group’s bottom half.

About Funds:

The firm maintains a long-standing relationship with well-respected subadvisor Wellington Management Company. Wellington has long run the firm’s equity funds–over half of its $116 billion in fund assets–and took the reins of Hartford Fund’s fixed-income platform beginning in 2012. In 2016, Hartford Funds began offering strategic-beta exchange-traded funds with its acquisition of Lattice Strategies and partnered with U.K.-based Schroders to expand its investment platform further. The Schroders alliance added another strong subadvisor to Hartford’s lineup, with expertise in non-U.S. strategies. Hartford Funds mostly leaves day-to-day investment decisions to its well-equipped subadvisors and instead steers product development, risk oversight, and distribution for its strategies. In 2013, the firm reorganized and grew its product-management and distribution effort. Since then, leadership has added resources to its distribution and oversight teams, merged and liquidated subpar offerings, introduced new strategies, evolved its strategic partnerships with MIT AgeLab and AARP, and lowered some fees. That said, fees are still not always best in class but have improved.

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Technology Stocks

PTC Continues Aggressive SaaS Transition to Fuel Future Growth; Raising FVE to $105

Business Strategy and Outlook

PTC operates in the high-end computer-assisted design software market, but Morningstar analyst view this market as mature and don’t foresee significant top-line growth in this area. PTC’s foray into growth areas such as “Internet of Things,” AR, and midmarket CAD, on the other hand, will significantly add growth to the top line, and as per Morningstar analysts view, PTC’s revenue mix to shift significantly to these areas over the next 10 years. 

PTC’s Creo software is considered a staple among many large assembly and complex product engineer teams, whether it’s in designing the efficient transportation of fluids or cabling. The small high-end CAD market compared with the mid-market has safeguarded PTC from new entrants to some extent. However, Morningstar analysts think the firm has largely been able to maintain its claim in the CAD industry based on its high switching costs, which as per Morningstar analysts apply not only to its core CAD offering but also its product lifecycle management software and new growth areas–like its Internet of Things and AR platforms. Still, switching costs alone aren’t enough to drive hefty growth in high-end CAD.

While Morningstar analysts expect a mix shift in the future for PTC, a shift to a subscription model from a license-based model is largely in the recent past. PTC has suffered only temporary declines in revenue, margins, and returns on invested capital, as per Morningstar analysts view. As per Morningstar analyst’s perspective, the company will be able to recover well from the transition as its converted subscribers mature.

With this expected recovery, PTC’s growth areas will be able to contribute to a much greater portion of PTC’s business due to strong partnerships. While PTC’s mid-market SaaS CAD software, Onshape, is within the company’s growth segment, and Internet of Things will see better success as entering the mid-market will be a tough task. In contrast, partnering with Microsoft and Rockwell Automation, PTC’s Internet of Things platform, Thingworx, has been able to gain greater traction for its solution that is widely known as among the best of breed.

PTC Continues Aggressive SaaS Transition to Fuel Future Growth; Raising FVE to $105

Narrow-moat PTC kicked off its fiscal year 2022 by posting results slightly below Morningstar analyst top- and bottom-line expectations. Nonetheless, results weren’t discouraging, as PTC is accelerating its SaaS transition, which brings with it short-term growth headwinds–but worthwhile benefits in the long term. Despite slight earnings misses, Morningstar analysts are raising its fair value estimate to $105 per share from $97, in most part due to rosier long-term corporate tax rates that Morningstar analysts have baked in after updating in-house estimates. Shares remained flat after hours, trading around $113 per share, leaving PTC fairly valued.

Financial Strength 

PTC to be in good financial health. As of fiscal 2021, PTC had a balance of cash and cash equivalents of $327 million and long-term debt at $1.4 billion. This leaves PTC with a debt/EBITDA ratio of 2.77 at fiscal year-end 2021. We estimate PTC’s growing base of cash and cash equivalents will be more than enough to support mild acquisition spend going forward, at an average of $50 million per year. Despite the company’s financial health, we do not foresee the company starting to issue dividends given the relatively significant transition PTC will undergo over the next 10 years, as per Morningstar analysts view, and the consequent possibility of additional cash needs as a result.

Bulls Say

  • PTC’s revenue should be able to grow significantly as its Internet of Things solutions take off. 
  • PTC’s Onshape platform makes headway in the midmarket as Autodesk and Dassault Systèmes are slow to move to a fully SaaS-based model. 
  • PTC should be able to improve gross margins as its low-margin services business comes down as a percentage of total revenue

Company Profile

PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as Internet of Things and AR industrial solutions. Founded in 1985, PTC has 28,000 customers, with revenue stemming mostly from North America (45%) and Europe (40%).

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Global stocks

Company books multiple records which results in increase of its fair value estimate

Business Strategy and Outlook:

Stifel Financial, along with other investment banks, had relatively strong revenue in 2020 that has been sustained in 2021 as economic uncertainty led to strong trading volume. Additionally, an initial need for capital in the recession and then low interest rates and a strong stock market led to high capital-raising activity.

Stifel Financial has a long history of being an active acquirer. The company ended 2020 with a Tier 1 leverage ratio of about 12% compared with a previously targeted 10%. With several hundred million dollars of arguably excess capital, the company could make some decent-size acquisitions. Barring growth through acquisitions, as valuations may be too high for most investment banks and investment managers, the company may see some growth from a renewed commitment to its independent advisor business.

Financial Strength:

Stifel’s financial health is fairly good. At the end of 2020, the company had approximately $1.1 billion of corporate debt and over $2 billion of cash on its balance sheet. Its next large debt maturity is $500 million in 2024.The company’s total leverage is less than 8, which is fair considering the mix of its investment banking and traditional banking operations. At the end of 2020, Stifel was at its disclosed target of a 11.9% Tier 1 leverage ratio. Given that its Tier 1 leverage ratio is above management’s previously stated target of 10%, the company should resume more material share repurchases or pursue acquisitions. Stifel has a history of making opportunistic acquisitions.

Bulls Say:

  • Stifel’s string of acquisitions has increased operational scale and expertise. 
  • Stifel is an experienced acquirer and integrator. A recession could provide ample acquisition opportunities. 
  • Net interest income growth over the previous several years at the company’s bank materially expanded wealth management operating margins, and the increased size of the bank and wealth management business provides diversification with its institutional securities business.

Company Profile:

Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 60% of the company’s net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial service firms.

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Daily Report Financial Markets

USA Market Outlook – 28 January 2022

Categories
Global stocks Shares

Rollins well positioned to fend off mounting inflationary pressures in 2022

Business Strategy and Outlook

Rollins’ strategy aims to further reinforce the density benefits afforded to its market-leading operations in the highly localized pest-control services markets, which it competes in, across North America. Ever-improving unit costs are offered by economies of density in each regional market in which Rollins operates. Rollins seeks to continue to amass these benefits via organic growth and continued focus on tuck-in acquisitions aimed at rolling up the fragmented North American pest-control service market. Recent investments in route optimization technology exemplify Rollins’ cost-out strategy, the continued roll-out of which is likely to widen EBIT margins. 

A sustainable cost advantage has accrued to Rollins as result of execution of the business’ strategy, leading to our wide-moat designation. Pest-control acquisitions and continuing focus on cost-out initiatives are key to the strategy. Nonetheless, Rollins remains equally focused on the defense of its leading North American market positions, noting the loss of customers quickly unwinds the operating-margin-widening benefits of density. Rollins requires annual training of all of pest-control technicians, while also limiting its own organic market share gains to maintain strong service levels and customer satisfaction.

Financial Strength

Rollins’ typically conservative balance sheet is in good health, sitting in a net debt position of $50 million at the end of 2021, or 0.1 times net debt/EBITDA. Rollins takes a highly prudent approach to the use of debt, typically using it only to act opportunistically when a quality acquisition target is in play and using subsequent operating cash flow to promptly retire debt. Alternatively, returning surplus capital to shareholders could also be considered. Rollins maintains $425 million in debt facilities, which provide the group with an additional source of liquidity. The facilities carry a leverage covenant of 3.0 times net debt/EBITDA and matures in April 2024.

Wide-moat Rollins capped off an already impressive 2021 performance with a strong fourth-quarter showing. 2021 adjusted EBITDA of $546 million tracked 2% ahead of our full-year expectations. On a constant-currency basis, full year organic sales grew at an elevated 8.7%, aligning with our expectations for a strong cyclical recovery in pest control demand in 2021. Tuck-in acquisitions added 2.7% in additional top-line growth in 2021 and drove the business’ modest outperformance relative to our revenue and earnings forecasts. Otherwise, Rollins’ late 2021 performance tracked in line with our long-term expectations for the U.S. pest control industry leader. 

Bulls Say’s 

  • The recent uptick in capital allocated to tuck-in acquisitions is likely to continue, supporting economies of scale and boosting operating margins. 
  • Phase 2 of the route optimization technology rollout looks to further widen Rollins’ EBIT margin. 
  • Increasing per-capita spending on pest control should support Rollins’ organic growth at a mid-single-digit clip.

Company Profile 

Rollins is a global leader in route-based pest-control services, with operations spanning North, Central and South America, Europe, the Middle East and Africa and Australia. Its portfolio of pest-control brands includes the prominent Orkin brand, market leader in the U.S.–where it boasts near national coverage–and in Canada. Residential pest and termite prevention predominate the services provided by Rollins, owing to the group’s ongoing focus on U.S. and Canadian markets. 

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Global stocks Shares

Abbott benefits from Omicron surge, but Covid-19 could turn to headwind in 2022

Business Strategy and Outlook:

Since 2013, Abbott has continued to improve the profitability of its four segments: nutritionals, devices, diagnostics, and established pharmaceuticals. Although the company has made progress over the last nine years, it still lags key rivals on profitability measures despite competing in businesses that are characterized by attractive margins. Abbott’s efforts to improve efficiency, including streamlining its distribution channels and building facilities in lower-cost locations like China and India, have demonstrated some success. But there is still room for improvement as we look at the company’s consolidated profitability.

As with all medtech companies, Abbott’s big challenge, over the longer term, is to fuel innovation. The bar for securing reimbursement for new technology has risen as payers have become more stringent about clinical data before committing to payment. While Abbott has seen recent success with FreeStyle Libre, we’re less impressed with its historical record on new product launches. Compared with key medical device competitors, including Boston Scientific, Medtronic, and Edwards Lifesciences, Abbott hasn’t cultivated similar revolutionary advancements. The firm’s forte seems to focus on incremental improvements to the existing technology platforms it has acquired over the last 15 years.

Financial Strength:

The fair value estimate of Abbott remains same at $104 per share, which assumes rapid diagnostics revenue will decline by 23% in 2022 as COVID-19 transitions to an endemic disease. That decline will be offset by ongoing recovery in non-pandemic procedure volume, and Abbott’s latest new product launches, including Amplatzer Amulet for left atrial appendage closure.

Abbott’s balance sheet is a pillar of strength and can weather the COVID-19 crisis with ease. The large acquisitions of St. Jude Medical and Alere increased leverage, and Abbott enjoyed relatively less financial flexibility during 2016-17 but remained steady enough to meet its debt obligations and continued to raise its dividend. More recently, Abbott’s debt/EBITDA has hovered just over 2 times, which reflects the firm’s ability to generates $4 billion-$5 billion in annual free cash flow, and closer to $7 billion thanks to the COVID-19 windfall. This also means Abbott can handily engage in more tuck-in acquisitions while also supporting sizable increases in its dividend.

Bulls Say:

  • Abbott has been investing in structural heart products and recently entered the left atrial appendage closure market. 
  • Early results from an investigational clinical trial on the Tendyne transcatheter mitral valve were favorable. If the pivotal trial results are favorable, this could give a boost to Abbott’s structural heart unit. 
  • Abbott’s sale of its established pharma business in developed markets to Mylan and its acquisition of CFR and Veropharm have put the branded generics business in a strong position to benefit from growing demand in emerging markets.

Company Profile:

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Daily Report Financial Markets

USA Market Outlook – 27 January 2022

Categories
Global stocks Shares

IFF Positioned for Long-Term Success as the Largest Global Specialty Ingredient Producer

Business Strategy and Outlook

International Flavors & Fragrances is a global leader in the specialty ingredients space. The company has grown rapidly via acquisition, having added DuPont’s nutrition and biosciences business in 2021 and Frutarom in 2018. IFF holds an enviable asset portfolio focused on value-added products used in food and beverages, fragrances, personal care, enzymes, probiotics, and pharmaceuticals. Its legacy business operated in the $20 billion-plus flavors and fragrances industry with a roughly 25% market share. Key competitors include Givaudan (25%), Firmenich (16%), and Symrise (12%). These four flavor and fragrance companies command roughly three fourths of the global market. IFF’s products affect the desired taste, smell, or mouth feel based on customer specifications.

IFF has four reporting segments divided by end market. Nourish is the largest segment, which generates a little over half of revenue. This segment holds IFF’s legacy taste segment and DuPont’s ingredients business, including plant-based protein formulations and other vital ingredients like texturants and emulsifiers.

Health and biosciences, which generates a little over 20% of revenue, is mostly the legacy Danisco industrial enzymes and cultures (probiotics) businesses. IFF has a roughly 20% share in both the enzymes market and the cultures market. 

The scent segment, consisting of IFF’s legacy fragrances business, generates a midteens percentage of revenue. IFF’s smallest component is pharma solutions, producing inactive ingredients such as excipients (pill binders) and time-release polymers.

 Proprietary formulations are critical drivers of revenue growth. For example, rather than supplying simple flavor solutions, IFF can deliver innovative solutions that modulate the consumer experience. These “fine-tuning” solutions can reduce costs for customers, allowing for the use of cheaper ingredients, extend a product’s shelf life, or add probiotic nutrition. Additionally, the company’s offerings help customers remove undesirable content (fat, sugar, and sodium) from a product without sacrificing the consumer experience.

Financial Strength

IFF has an elevated debt level, thanks to the roughly $10 billion in debt that the company raised to fund the DuPont nutrition and biosciences and Frutarom acquisitions. As of Sept. 30, 2021, total debt was a little over $11.5 billion and the company held roughly $0.8 billion in cash and cash equivalents. Management reported a net financial debt/adjusted EBITDA ratio of 4.1 times as of Sept. 30, 2021. However, management plans to use excess cash flow to repay debt, toward the goal of achieving a net debt/EBITDA ratio of less than 3 times by early 2024, or 36 months after the DuPont nutrition and biosciences acquisition closed. While IFF will carry elevated leverage, its indebtedness should prove manageable, given the relatively stable cash flows we expect the company to generate. Further, IFF is undergoing a portfolio review to divest noncore assets as a way to accelerate debt reduction, such as the microbial control divestiture in 2022 for $1.3 billion. As such, we believe IFF should be able to meet all of its financial obligations, including dividends, pensions, and postemployment benefit liabilities.

Bulls Say’s

  •  As the largest specialty ingredients producer globally, IFF holds an enviable portfolio of market-leading products spanning multiple industries.
  • The company is well positioned to capitalize on further growth in developing markets, where it generates the most sales.
  • IFF’s high R&D spending (around 6% of sales) acts as a barrier to entry, underpins innovation, and promotes future growth

Company Profile 

International Flavors & Fragrances produces ingredients for the food, beverage, health, household goods, personal care, and pharmaceutical industries. The company makes proprietary formulations, partnering with customers to deliver custom solutions. The nourish segment, which generates roughly half of revenue, is a leading flavour producer and also sell texturants, plant-based proteins, and other ingredients. The health and biosciences business, which generates around one fourth of revenue, is a global leader in probiotics and enzymes. IFF is also one of the leading fragrance producers in the world. The firm also sells pharmaceutical ingredients such as excipients and time-release polymers.

(Source: MorningStar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Global stocks Shares

American Airlines Group Inc. : An 80%-90% recovery in business travel that consequently increases at GDP levels over the average term.

Business Strategy and Outlook

American Airlines is the largest U.S.-based carrier by capacity. Before the coronavirus pandemic, much of the company’s story was based on realizing cost efficiencies from its transformational 2013 merger with U.S. Airways and strengthening the firm’s hubs to expand margins. While we think that American Airlines has done a good job at limiting unit cost increases, we note that the firm lagged peers in unit costs over the previous aviation cycle. Management sees the pandemic crisis as an opportunity to structurally improve the firm’s cost position relative to peers.

In the leisure market, it is expected low-cost carriers to prevent American Airlines from increasing yields with inflation. American’s basic economy offering effectively serves the leisure market, it is not expected that the firm to thrive in this segment. A leisure-led recovery in commercial aviation is anticipated, reflecting customers being more willing to visit friends and family and vacation in a pandemic than they are to go on business travel.

American Airlines will participate in the recovery of business and international leisure travel after a vaccine for COVID-19 becomes available. It is suspected that a recovery in business travel will be critical for American, as the firm’s high-margin frequent-flier program is closely tied to business travel. Business travellers will often use miles from a co-branded credit card to upgrade flights when their company is unwilling to pay a premium price. Banks pay top dollar for frequent-flier miles, which gives American a high-margin income stream.

The COVID-19 pandemic has presented airlines with the sharpest demand shock in history, and many of our projections are based on our assumptions around how illness and vaccinations affect society. We’re expecting a full recovery in capacity and an 80%-90% recovery in business travel that subsequently grows at GDP levels over the medium term.

Financial Strength

American is the most leveraged U.S.-based major airline due to its fleet renewal program and from the COVID-19 pandemic. As the pandemic has wreaked havoc on air travel demand and airlines’ business model, liquidity has become more important in 2020 than in recent years. American Airlines, more than peers, increased leverage, and diluted equity during the COVID-19 pandemic. We think American Airlines’ comparably higher financial leverage will make it difficult for the firm to maneuver going forward, and that management will have few capitals allocation options other than deleveraging post-pandemic. American Airlines came into the crisis with considerably more debt than peers, with gross debt to EBITDA sitting at roughly 4.5 times in 2019. American ended 2021 with $38.1 billion of debt and $13.4 billion of cash. It is expected that American Airlines will use incremental free cash flow to deleverage after the crisis. We anticipate EBITDA expansion and debt reductions will reduce gross debt/EBITDA to roughly two to three turns in the 2025-26 timeframe. The firm has $2.6 billion of debt coming due in 2022, and we expect that the firm will use cash on the balance sheet to pay the debt.

Bulls Say’s

  • American Airlines has the youngest fleet among U.S. major airlines, which should dampen fuel expense and maintenance going forward.
  • American Airlines has largely completed its fleet renewal, which should decrease capital expenditures going forward.
  • Leisure travellers are becoming more comfortable with flying during the COVID-19 pandemic

Company Profile

American Airlines is the world’s largest airline by scheduled revenue passenger miles. The firm’s major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.

(Source: Morningstar)

General Advice Warning

Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.

Categories
Daily Report Financial Markets

USA Market Outlook – 25 January 2022